Details for Patent: 7,872,050
✉ Email this page to a colleague
Which drugs does patent 7,872,050 protect, and when does it expire?
Patent 7,872,050 protects VALCHLOR and is included in one NDA.
This patent has forty-eight patent family members in twenty countries.
Summary for Patent: 7,872,050
Title: | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Abstract: | A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of a Nitrogen Mustard or a HX salt of the Nitrogen Mustard to the affected skin, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol, wherein the non-aqueous vehicle or carrier does not include petrolatum or ethanol. |
Inventor(s): | Alonso; Robert (Philadelphia, PA), Crooks; Peter A. (Nicholasville, KY), Pimley; Mark A. (Glenmoore, PA) |
Assignee: | Yaupon Therapeutics Inc. (Radnor, PA) |
Application Number: | 11/369,305 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 7,872,050
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Helsinn | VALCHLOR | mechlorethamine hydrochloride | GEL;TOPICAL | 202317-001 | Aug 23, 2013 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,872,050
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2006223076 | ⤷ Try a Trial | |||
Canada | 2600468 | ⤷ Try a Trial | |||
China | 101175735 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |